Big Biotech’s Value Is Bolstered by Focus on Alzheimer’s Disease

Source: Streetwise Reports   11/01/2017 An analysis of this company’s quarterly update highlights a pipeline studded with candidates targeting neurological indications. In an Oct. 25 research report, H. C. Wainwright analyst . . . → Read More: Big Biotech’s Value Is Bolstered by Focus on Alzheimer’s Disease Similar Articles: Gout, Kidney Stones, Liver Disease & Cannabinoids Progress in Pain Control and Liver Disease Programs Spurs Rise in Company’s Rating Biotech with Alzheimer’s Focus Makes Progress on Several Fronts